By JNi.Media – 8 Kislev 5778 – November 26, 2017
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products based in Haifa, Israel, announced last week that the US Patent and Trademark Office had issued it a patent titled, “Skeletal muscle regeneration using mesenchymal system cells.”
Mesenchymal stromal cells are spindle-shaped plastic-adherent cells isolated from bone marrow (BM), adipose tissue and other organs, including the placenta.
This key patent, which has already been granted the company in Europe, Hong Kong and Israel, addresses the use of MSCs for skeletal muscle regeneration used either directly after, or shortly after, post-surgical muscle injury.
Artificial intelligence creates content for the site, no worse than a copywriter, you can also use it to write articles. 100% uniqueness :). Click Here:👉 https://stanford.io/3FXszd0